Related Experiment Video
Updated: May 4, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
36.1K
Association between phosphodiesterase 4D polymorphism SNP83 and ischemic stroke
Yan Yan1, Xiuping Luo2, Jinlu Zhang2
1Department of Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Journal of the Neurological Sciences
|December 25, 2013
Summary
This meta-analysis confirms a link between the PDE4D gene
Area of Science:
- Genetics
- Neurology
- Epidemiology
Background:
- The phosphodiesterase 4D (PDE4D) gene was initially linked to ischemic stroke (IS) in 2003.
- Previous research on the association between PDE4D and IS has yielded contradictory findings.
Purpose of the Study:
- To conduct a comprehensive meta-analysis to clarify the association between the PDE4D gene (SNP83 polymorphism) and ischemic stroke risk.
Main Methods:
- A systematic literature search was performed across PubMed, Embase, and four Chinese databases up to January 2013.
- Meta-analysis techniques were employed, calculating odds ratios (OR) with 95% confidence intervals (CI).
- Twenty-five studies involving 8878 cases and 12306 controls were included.
Main Results:
- A significant association was found between the PDE4D gene (SNP83) and ischemic stroke risk in the overall population.
- This association was particularly notable in Asian and Chinese populations.
- No significant association was observed in the Caucasian population across various genetic models.
Conclusions:
- The PDE4D gene (SNP83 polymorphism) is associated with ischemic stroke risk in overall and Asian/Chinese populations.
- The findings were consistent over a cumulative meta-analysis from 2009 to 2012, indicating a stable trend.
- The association was not significant among Caucasian individuals.
More Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:11Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138